Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer-Reference-Cited by-同舟云学术

Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer

Published:2019-12 Issue:7 Volume:51 Page:673-680
ISSN:0031-3025
Container-title:Pathology
language:en
Short-container-title:Pathology

Author:

Pavlakis Nick,Cooper Caroline,John Thomas,Kao Steven,Klebe Sonja,Lee Chee Khoon,Leong Trishe,Millward Michael,O'Byrne Ken,Russell Prudence A.,Solomon Benjamin,Cooper Wendy A.,Fox Stephen

Funder

Pfizer Ltd Australia

Pfizer

AstraZeneca

Roche

Bristol-Myers Squibb

Merck

Sharp & Dohme

Teva

Boehringer Ingelheim

Pfizer/EMD Serono

Novartis

Janssen

Mundipharma

Publisher

Elsevier BV

Subject

Pathology and Forensic Medicine

Reference53 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018

2. Cancer in Australia,2019

3. Testing for ROS1 in non-small cell lung cancer: a review with recommendations;Bubendorf;Virchows Arch,2016

4. Recent advances in targeting ROS1 in lung cancer;Lin;J Thorac Oncol,2017

5. IASLC Atlas of ALK and ROS1 Testing in Lung Cancer,2016

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Importance of Testing for ROS1 Rearrangements in Non-Small Cell Lung Cancer in the Era of Targeted Therapy in a Latin American Country;Cancer Management and Research;2024-07

2. Current treatment and novel insights regarding ROS1‐targeted therapy in malignant tumors;Cancer Medicine;2024-04

3. Clinical Application of Blocker Displacement Amplification Technique Combined with Next Generation Sequencing in Liquid Biopsy of Advanced Non-Small Cell Lung Cancer with Positive Anaplastic Lymphoma Kinase and Repressor of Silencing 1 Fusion Genes;J BIOL REG HOMEOS AG;2022

4. Molecular Targetable Pathways and Therapy—ROS1;Encyclopedia of Respiratory Medicine;2022

5. ROS1 in non-small-cell lung carcinoma: A narrative review;Cancer Research, Statistics, and Treatment;2022